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Somatic neurofibromatosis type 1 (NF1) inactivation
characterizes NF1-associated pilocytic astrocytoma
David H. Gutmann,1,2,7 Michael D. McLellan,3,4 Ibrahim Hussain,1 John W. Wallis,3,4
Lucinda L. Fulton,3,4 Robert S. Fulton,3,4 Vincent Magrini,3,4 Ryan Demeter,3,4
Todd Wylie,3,4 Cyriac Kandoth,3,4 Jeffrey R. Leonard,5 Abhijit Guha,6
Christopher A. Miller,3,4 Li Ding,3,4 and Elaine R. Mardis2,3,4,7
1

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA; 2Alvin J. Siteman Cancer
Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA; 3The Genome Institute at Washington University
School of Medicine, St. Louis, Missouri 63110, USA; 4Department of Genetics, Washington University School of Medicine, St. Louis,
Missouri 63110, USA; 5Division of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA;
6
Department of Neurosurgery, University of Toronto, Labatt Brain Tumor Centre, Toronto, Canada M5G 1X8
Low-grade brain tumors (pilocytic astrocytomas) arising in the neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome are hypothesized to result from a combination of germline and acquired somatic NF1 tumor suppressor gene mutations. However, genetically engineered mice (GEM) in which mono-allelic germline Nf1 gene loss is
coupled with bi-allelic somatic (glial progenitor cell) Nf1 gene inactivation develop brain tumors that do not fully recapitulate the neuropathological features of the human condition. These observations raise the intriguing possibility that,
while loss of neurofibromin function is necessary for NF1-associated low-grade astrocytoma development, additional
genetic changes may be required for full penetrance of the human brain tumor phenotype. To identify these potential
cooperating genetic mutations, we performed whole-genome sequencing (WGS) analysis of three NF1-associated pilocytic
astrocytoma (PA) tumors. We found that the mechanism of somatic NF1 loss was different in each tumor (frameshift
mutation, loss of heterozygosity, and methylation). In addition, tumor purity analysis revealed that these tumors had
a high proportion of stromal cells, such that only 50%–60% of cells in the tumor mass exhibited somatic NF1 loss.
Importantly, we identified no additional recurrent pathogenic somatic mutations, supporting a model in which neuroglial
progenitor cell NF1 loss is likely sufficient for PA formation in cooperation with a proper stromal environment.
[Supplemental material is available for this article.]
NF1 is one of the most common autosomal dominant tumor predisposition syndromes in which affected individuals develop brain
tumors. In this regard, 15%–20% of children with NF1 develop
World Health Organization (WHO) grade I pilocytic astrocytomas
(PAs) (Listernick et al. 1994). These low-grade glial neoplasms
typically arise in children <7 yr of age and most commonly occur
in the optic pathway (optic nerves, chiasm, and tracts) or in the
brainstem (Listernick et al. 1997). Similar to other tumor predisposition syndromes, children with NF1 are born with one mutated, nonfunctional copy of the NF1 gene, such that loss of the
remaining allele in appropriate progenitor cells enables tumorigenesis. Consistent with this ‘‘two hit’’ hypothesis, previous
studies of NF1-associated PA (NF1-PA) have demonstrated loss of
heterozygosity at the DNA level (Kluwe et al. 2001; Gutmann et al.
2003) and loss of NF1 protein (neurofibromin) expression (Gutmann
et al. 2000).
While NF1 loss in neuroglial progenitors is necessary for PA
formation in individuals with NF1, genetically engineered mice
(GEM) with conditional loss of Nf1 gene expression in neuroglial
progenitor cells fail to develop brain tumors (Bajenaru et al. 2002;
Zhu et al. 2005). This failure to develop gliomas reflects the need

for cooperating Nf1+/ non-neoplastic cells in the tumor microenvironment. In this regard, similar to children with NF1 harboring one nonfunctional and one functional NF1 allele in every cell
of their bodies, Nf1+/ mice (one functional and one inactivated
Nf1 allele) with absent neuroglial progenitor Nf1 expression develop optic gliomas with nearly 100% penetrance (Bajenaru et al.
2003). Similar to their human counterparts, these murine brain
tumors exhibit low levels of proliferation, increased numbers
of endothelial cells and microglia, and nuclear pleomorphism
(Bajenaru et al. 2005; Kim et al. 2010).
Interestingly, these mouse optic gliomas do not fully recapitulate the classic histopathological features of the human tumors, in that they lack Rosenthal fibers and eosinophilic granular
bodies (Louis et al. 2007), raising the intriguing possibility that
other genetic alterations exist in human NF1-PA. The purpose of
the current study was to employ advanced whole-genome sequencing technologies to establish the genomic landscape of human NF1-PA to facilitate the development of improved approaches
to the diagnosis and management of these brain tumors.

7

Whole-genome sequencing (WGS) was performed on three PAmatched normal blood (PBMC) cases from individuals with NF1
established using NIH Consensus Development Conference diagnostic criteria (Stumpf et al. 1988; Gutmann et al. 1997). These
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tumors are difficult to obtain, as they are rarely surgically resected
and, when removed, typically provide very limited amounts of
frozen tissue for comprehensive analysis. Based on our previous
studies (Leonard et al. 2006), we specifically selected three PA tumors that were atypical by virtue of patient age (>7 yr of age at the
time of glioma discovery) and tumor location (outside of the optic
pathway) to maximize our ability to detect additional causative
mutations (Table 1). All of these tumors contained >90% tumor
(and not normal surrounding brain) by routine hematoxylin and
eosin histopathologic review, exhibited the classic histopathologic
features of PA (eosinophilic granule bodies, Rosenthal fibers), had
low proliferative indices, and lacked necrotic areas or mitotic figures.
Informed consent was obtained for all patients on an active protocol
approved by the Washington University School of Medicine Institutional Review Board. We obtained paired end sequencing data
to a minimum average depth of >32-fold haploid depth per genome. An overall concordance of >99% was obtained when
comparing WGS-derived SNP genotypes with SNP array data at
identical genome positions (Supplemental Table 1).
In all three patients, the germline NF1 mutations were
identified based on their presence in both tumor and blood DNA
(Table 1; Fig. 1): T01 had a point mutation (c.2002-14) in intron
17 (NM_001042492.2) previously demonstrated to create a novel
splice variant (Spurlock et al. 2010); T02 had a germline splice site
mutation (c.205-2), while T03 had a germline nonsense mutation
(p.W1662*). Despite the use of both PCR and capillary sequencing
as well as targeted capture-based sequencing from validation, we
only identified a somatic NF1 gene mutation in T02 (frameshift
mutation; p.C2426fs), suggesting that additional second hit mechanisms were responsible for low-grade astrocytoma formation in the
other two tumors. Moreover, no mutations were identified in the
putative promoter region encompassing 50 kb 59 of the initiation
codon.
To exclude the possibility that T01 and T03 retained NF1 gene
expression, we performed immunohistochemistry to demonstrate
loss of neurofibromin protein expression in all three NF1-PA tumors (Fig. 2A), a result consistent with complete NF1 inactivation
in NF1-PA tumors. We next sought to define the mechanism(s)
underlying loss of the second allele in T01 and T03. Loss of heterozygosity (LOH) analyses were performed using VarScan-2
(Koboldt et al. 2012), requiring a variant allele frequency at heterozygous germline SNPs of $10% in the normal sample and of
either #5% or $95% in the tumor (only high-confidence calls were
considered) to identify LOH regions. Using this method, we
identified a 57.3 Mbp copy-neutral LOH on the q arm of chromosome 17 from position 23.9 Mbp to the telomere, encompassing the NF1 gene, in T03 (Fig. 2B). Further examination of supporting variant and reference allele frequencies indicated bi-allelic
inactivation of the NF1 gene in this tumor occurred through

Table 1.
ID

Age

T01

20

T02
T02
T03

18
18
12

a

Clinical attributes and NF1 mutations in the three NF1-PA tumors
Sex

Tumor
location

Male

Mutation
class

Lower medulla de novo splice
site
Female Hypothalamus Splice site
Female Hypothalamus Frameshift
Female Temporal lobe Nonsense

Transcript NM_001042492.
Variant allele frequency.

b
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duplication of the p.W1662* nonsense germline mutation and loss
of the wild-type NF1 allele.
Since T01 had neither an identified somatic NF1 mutation nor
clear evidence of LOH based on the VarScan analysis of 81 heterozygous sites within the NF1 gene (mean VAFs: 49.2% in the normal
DNA and 55.6% in the tumor DNA), we examined methylation
patterns. Using the Illumina Infinium HumanMethylation450
BeadChip, we assayed the three whole-genome-sequenced NF1-PA
samples and two additional sporadic PA tumors. Genome-wide
analysis comparing T01 with T02 and T03 identified 118 probes
clustered in 105 regions that exhibited significantly different
methylation (Supplemental Table 2). Upon further examination,
no methylation alterations affected genes previously reported to be
mutated in sporadic PA tumors (Wimmer et al. 2002b; Tada et al.
2003; Sharma et al. 2005; Deshmukh et al. 2008; Jones et al. 2008;
Pfister et al. 2008). For most of the 42 probes localized within the
NF1 gene region, we found that methylation patterns were similar in all five PA tumor samples analyzed. However, as a group,
the NF1-PA tumors exhibited increased methylation (greater
than two standard deviations) at probe cg21850879 (NCBI 36
chr17:26646069) compared with the sporadic counterparts. Interestingly, in T01 (the tumor lacking a second NF1 somatic mutation) there was increased methylation (greater than two standard
deviations) at probe cg13759778 (NCBI 36 chr17:26648522)
compared with T02 and T03. Probe cg13759778 is within 200 bp
of the transcription start site of OMG, one of three antisense
nested genes within intron 27b of the NF1 gene (intron 36 of
NM_001042492.2) (Fig. 2C). While this methylation event occurs
in intronic sequences within the NF1 locus and cannot be definitively demonstrated to cause NF1 gene silencing, the absence of
neurofibromin expression in this tumor is consistent with loss of
NF1 gene expression from this allele. Together, these data support
the existence of multiple distinct mechanisms (mutation, LOH,
and methylation) underlying somatic NF1 inactivation in NF1-PA
tumors.
Using WGS, we were also able to accurately quantify the NF1
mutant allele frequencies and determine the relative clonality
and cellular heterogeneity of these low-grade glial cell neoplasms
(Ding et al. 2012). For clonality estimates, we evaluated data for
somatic SNVs in nonrepetitive regions consisting of validated
nonsynonymous coding variants, and high-confidence, manually
reviewed events in potential regulatory regions, as well as the
remaining nonrepetitive portion of the genome, representing a
total of 133, 181, and 94 variants for tumors T01, T02, and T03,
respectively (Supplemental Tables 3–5). Single clusters identified
by kernel density estimation (Fig. 3A) indicated that each tumor
consisted primarily of a single founding clone having no subclones.
We used these analyses to calculate tumor purity, and found
that these tumors were composed of 49%–64% non-neoplastic
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Type

NCBI 36
position

Alleles

Effecta

SNP Chr17:26577565 C > G p.D668fs

Status
Germline

SNP Chr17:26510152 A > C p.R69fs
Germline
DEL Chr17:26700349 T > — p.C2426fs Somatic
SNP Chr17:26677113 G > A p.W1662a Germline + LOH

Validation VAFb Validation VAFb
tumor
normal
64.7%

47.6%

49.7%
23.4%
75.3%

44.8%
0%
46.7%

Tumoral NF1 loss is sufficient for PA formation

Figure 1. NF1 truncation mutations in three whole-genome-sequenced
NF1-PA tumors. The locations of all truncation mutations are designated
with a circle mapped to transcript NM_001042492. Truncating mutations were initially identified in WGS data and further validated with
targeted approaches. Predicted functional effects are based on transcript
NM_001042492. In patient T03, a somatic, copy-neutral LOH of 57.3 Mbp
resulted in duplication of the p.W1662* germline variant.

cells. Based on the combination of tumor purity and the coverage
obtained from WGS data, the estimated sensitivity of our somatic
mutation detection process is 70%. The large contribution of
NF1+/ non-neoplastic cells to the tumor cellularity is consistent
with parallel microglia (CD68+ cells) immunostaining results
(Fig. 3B), where 35%–55% of the cells in these PA tumors were
microglia/macrophages. This level of stromal contamination with
microglia/macrophages is similar to that observed in both sporadic
low-grade and high-grade gliomas (Simmons et al. 2011).
Next, we evaluated that possibility of large-scale somatic
rearrangements in other genes potentially cooperate with NF1 loss
during PA formation or growth by performing copy number alteration analysis of WGS read data using the cnvHMM algorithm
(Chen et al. 2012). Importantly, read-count analysis showed no
evidence of copy number aberrations (CNA) in the NF1 gene regions in any tumor (Supplemental Fig. 1). We then employed
BreakDancer (Chen et al. 2009) and SquareDancer (derived from
CREST [Wang et al. 2011]) to predict structural variants (SVs),
Based on the detection of aberrant mate-pair read mapping distance or orientation, BreakDancer predicted 921, 825, and 449
putative somatic SVs in samples T01, T02, and T03, respectively.
None of the predicted somatic SVs were supported by reads containing a physical breakpoint identified by SquareDancer, no large
deletions were accompanied by corresponding drops in coverage,
and no SV events were validated by custom capture or PCR-based
validation sequencing. In this analysis, no CNV or SV were confirmed in the NF1-PA tumors, thus excluding CNA and SV from
possibly altering the NF1 locus or its partners.
Predicted nonsynonymous somatic mutations that affect
coding regions were validated using PCR followed by capillary sequencing (Supplemental Table 3). In contrast to previous reports
on PA, we found no copy number changes or mutations in the
BRAF, RAS (including KRAS, NRAS, and HRAS), MATN2, HIPK2,
PTEN, TP53, CDKN2A, or EGFR genes (Tada et al. 2003; Fishbein
et al. 2005; Sharma et al. 2005; Deshmukh et al. 2008; Jones et al.
2008; Pfister et al. 2008). However, nonsynonymous somatic
mutations were identified in DST and SVIL in patient T01, OR13C3
in T02, and GPATCH2, FYTTD1, ACTBL2, PIK3R2, and ZNF257 in
T03. To address the possibility that these somatically mutated
genes could be involved in NF1-PA tumorigenesis, we used custom
hybrid capture product sequencing to screen the coding exons of
ACTBL2, DST, GPATCH2, OR13C3, PIK3R2, SVIL, FYTTD1, and
ZNF257 in PA tumor samples from three additional NF1 patients.
No additional somatic mutations were identified in these additional

samples. Due to the low background mutation rate (BMR) in NF1-PA
tumors compared with other solid tumor types, mutations identified in noncoding regions were not included in the recurrent
screening efforts. Previous attempts to identify recurrent noncoding mutations in larger cohorts of solid tumors with higher
BMRs have only identified a small number of recurrent mutations
outside of coding regions (Ellis et al. 2012).
While these somatic mutations are novel, it is unlikely that
they are pathogenic. First, the majority of the mutations identified
(OR13C3, ACTBL2, FYTTD1, PIK3R2, and ZNF257) were revealed
to be neutral (conservative changes in the protein sequence by in
silico evaluation with Polyphen2 [Adzhubei et al. 2010], SIFT [Ng
and Henikoff 2003], and Condel [Gonzalez-Perez and Lopez-Bigas
2011]) using pre-computed values from the Ensembl Variant Effects Predictor (Supplemental Table 3). Second, of the mutations in
DST, SVIL, and GPATCH2 predicted to be deleterious, none occurred in an annotated functional protein domain related to carcinogenesis (Sigrist et al. 2010). Third, none of these eight mutations were identified in more than a single tumor, and thus were
not recurrent in the limited number of these uncommonly banked
tumors. Fourth, none of these genes exhibited bi-allelic inactivation
either by mutation or methylation.
Finally, it had been previously postulated that the mutation
frequency was high in individuals with NF1, with estimates
ranging between 1.4 3 104 (Crowe et al.1956) and 6.5 3 105
gamete/generation (Samuelsson and Axelsson 1981; Huson et al.
1989; Clementi et al. 1990). Here, in contrast, using WGS data, we
find that the mutation frequency in NF1-PA is relatively low,
similar to that of other pediatric solid tumors where carcinogenesis
often results from antecedent germline mutations. In T01, T02,
and T03, the BMR, excluding noncoding repetitive sequence, was
9.0 3 108, 1.2 3 107, and 6.0 3 108 mutations per sequenced
base, respectively, comparable with the BMRs of several pediatric
retinoblastoma genomes (Zhang et al. 2012a) (2.0 3 108, 5.0 3
108, 8.0 3 108, and 9.0 3 108). These mutation frequencies
differ slightly from hematological malignancies, such as pediatric
TALL and the M1 and M3 subtypes of adult AML (2.0 3 108 to
4.1 3 108 mutations per base) (Mardis et al. 2009; Welch et al.
2012; Zhang et al. 2012b), and differ markedly from adult solid
tumors, such as luminal breast cancer, that often have rates that are
orders of magnitude higher (Fig. 3C; Mardis et al. 2009).

Discussion
This study represents the first WGS analysis of low-grade glioma
and the first such examination of such tumors arising in the context of a common inherited brain tumor predisposition syndrome.
Moreover, these data provide important information about the
genomic landscape of NF1-PA, the clonal origins of these tumors,
the various mechanisms underlying somatic NF1 tumor suppressor
gene inactivation, and the extent of tumor cellular heterogeneity.
First, we employ WGS to show that bi-allelic NF1 gene inactivation is the primary genomic mutation in two of the three
NF1-associated PA tumors. While we identified other genetic
changes in each of the NF1-PA specimens, none of these mutations
were found in more than one tumor, none exhibited bi-allelic inactivation, and none were located within a predicted functional
domain of the encoded protein. Consistent with our previous
studies (Li et al. 2001), no changes in the TP53, CDKN2A, RB1,
EGFR, or CDK4 genes were observed. Together, these data favor the
time-honored hypothesis that NF1 loss in the neoplastic cellular
compartment is the key mutational driver of NF1-PA tumorigenesis.
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Figure 2. Mechanism of somatic NF1 inactivation. (A) Immunohistochemistry using rabbit polyclonal neurofibromin antibodies demonstrates positive
immunoreactivity in the normal human brain (HBr). (Inset) Single neuron with neurofibromin expression. In each of the three NF1-PA specimens, no
neurofibromin expression was detected. Scale bars, 100 mm. Magnification, 4003. Inset, 6003. (B) In T03, a somatic copy-neutral LOH of the q arm of
chromosome 17 from position 23.9 Mbp to the telomere results in duplication of the NF1 W1662* germline variant. Shown are the median variant allele
frequencies of high-confidence germline heterozygous SNPs identified in the normal DNA in 100,000-bp bins across chromosome 17. The position of
the NF1 gene is indicated. (C ) Methylation changes in T01 relative to T02 and T03 from Illumina Infinium HumanMethylation450 arrays for
42 probes spanning the NF1 genomic region. T01 exhibits increased methylation (>2 standard deviations) at NCBI 36 chr17:26648522 (probe
cg13759778). This location is within 200 bp of the transcription start site of OMG, one of three antisense nested genes within intron 36 of NF1 mRNA
NM_001042492.2.
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Figure 3. NF1-PA tumor clonality, cellular heterogeneity, and mutation rate. (A) Somatic mutation clusters were defined based on allele-specific
supporting read counts in whole-genome data for mutations identified in nonrepetitive genomic with diploid copy number. Kernel density estimation
indicates a monoclonal origin for each tumor and reveals a substantial proportion of stromal cells in the tumor biopsy with estimated tumor purities of
35%, 51%, and 39% for T01, T02, and T03, respectively. (B) CD68 immunostaining confirms the marked cellular heterogeneity of NF1-PA tumors, with
35%–55% of the cells in these tumors representing microglia/macrophages. Representative photomicrographs are included for each NF1-PA tumor. Scale
bar, 100 mm. Magnification, 4003. Insets, 6003. (C ) BMRs are based on the total sum of somatic mutations identified in all nonrepetitive genomic regions
from WGS of three NF1-PA tumors, and compared with pediatric retinoblastoma (N = 4) (Zhang et al. 2012a), pediatric TALL (N = 8) (Zhang et al. 2012b),
the M1 and M3 subtypes of adult AML (N = 25) (Welch et al. 2012), and luminal breast cancer (N = 46).

Second, we demonstrate that NF1-PA have a monoclonal origin, similar to their sporadic counterparts (Payton et al. 2011). While
the majority of studies that examined clonal origins of glioma using
single X-chromosome loci, fluorescent in situ hybridization, microsatellite markers, or single substitute mutation methods demonstrated a monoclonal pattern (Kattar et al. 1997; Zhu et al. 1997;
Mueller et al. 2001), there are reports of gliomas exhibiting a multiclonal origin (Dong et al. 2002; Gomori et al. 2002; Vital et al. 2010).
Since the few brain tumors with presumed polyclonal origins were
high-grade gliomas, we favor a model of low-grade pediatric astrocytoma development in which tumors arise from a single population
of glial progenitors during fetal or early postnatal life.
Third, we show that there exist multiple possible mechanisms
of somatic NF1 gene silencing, including LOH, mutation, and
methylation. While LOH and mutation have been reported in

numerous NF1-associated tumor types, prior studies on another
NF1-associated tumor (peripheral nerve sheath tumor; neurofibroma) revealed that NF1 promoter hypermethylation is a rare
‘‘second hit’’ event (Horan et al. 2000; Wimmer et al. 2002a; Harder
et al. 2004; Fishbein et al. 2005). While we have not demonstrated
a direct cause-and-effect relationship between NF1 locus hypermethylation and reduced NF1 gene expression, the finding that
absent neurofibromin (immunohistochemistry) expression was
observed in T01 is consistent with this conclusion. Our observations coupled with results on another childhood nervous system
tumor, retinoblastoma (Zhang et al. 2012a), suggest that somatic
tumor suppressor gene inactivation by methylation may represent
another mode to achieve bi-allelic inactivation. However, it is
possible that other mechanisms are operative, such as epigenetic
silencing by microRNA.
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Last, Nf1 GEM optic glioma models have been particularly
instructive in elucidating the requirements for tumorigenesis.
Collectively, these studies have revealed that the unique pattern of
low-grade astrocytoma development (predominantly in the optic
pathway/brainstem of children) reflects the coupling of at least
two requirements: (1) Nf1 loss in specific neuroglial progenitor
cells (third ventricle or brainstem) during a defined temporal
window (embryonic development) (Lee et al. 2010, 2012) and (2)
a supportive local microenvironment composed of critical molecular signals (Warrington et al. 2007, 2010) and non-neoplastic cell
types (Daginakatte and Gutmann 2007; Daginakatte et al. 2008).
The current study emphasizes the significant cellular heterogeneity in human NF1-PA, consistent with previous studies on glioma
in which a large proportion of the cellular composition is nonneoplastic cells. One of these stromal cell types is microglia, an
immune-like cell, analogous to macrophages outside of the central
nervous system (Graeber et al. 2002; Watters et al. 2005). The importance of these stromal cells to NF1 glioma growth is further
supported by several studies using Nf1 GEM strains. In these experiments, pharmacologic or genetic silencing of microglia reduces
glioma growth and proliferation (Daginakatte and Gutmann 2007;
Daginakatte et al. 2008; Simmons et al. 2011). The mechanism
underlying their glioma-promoting properties has not been fully
elucidated, but likely involves the generation of growth factors and
chemokines (Daginakatte and Gutmann 2007; Warrington et al.
2007; Wesolowska et al. 2008; Zhai et al. 2011). This potentially
instructive contribution of microglia has recently prompted us to
apply RNA sequencing methods to more comprehensively define
the role of microglia in sporadic PA formation and continued
growth.

Methods
Patients
Blood and tumor specimens were obtained from three patients
diagnosed with NF1 according to established criteria (Stumpf et al.
1988) treated at Washington University School of Medicine or
the University of Toronto under active Human Studies Protocols
approved by the Institutional Review Board at the Washington
University School of Medicine and the University of Toronto. WGS
was performed for tumor and normal DNA from three children with
pilocytic astrocytomas. Tumor samples were obtained from banked
resected tumors characterized by pathologic examination. Matched
nontumor samples were obtained from PBMCs by phlebotomy.

Custom capture hybridization and sequencing
Sequencing libraries were hybridized to biotinylated 120-mer oligonucleotide probes designed to cover all coding exons of target
genes. Illumina library quantification was completed using the
KAPA SYBR FAST qPCR Kit (KAPA Biosystems).

SNV and small indel detection
Candidate point mutations were predicted using SomaticSniper,
previously referred to as glfSomatic 1.5. Putative SNVs with somatic score $40 and average mapping quality $40 were considered high-confidence (HC); all others were deemed low-confidence
(LC). Small indels were predicted using a combination of GATK 6
IndelGenotyper, Pindel 7, and a modified version of SAMtools 3.
Both SNVs and indels were annotated using gene structure, conservation information, and regulatory potential, then binned as
previously described (Mardis et al. 2009). High-confidence noncoding mutations in nonrepetitive genomic regions were visualized to filter false positives, while nonsynonymous coding mutations were selected for additional PCR- and custom-capture-based
validation sequencing.

Copy number variation (CNV) analysis
Copy number calls from WGS data were generated using the
cnvHMM algorithm (http://genome.wustl.edu/software/cnvhmm).
First, cnvHMM divided the genome into nonoverlapping windows
10 kbp in size. For each window, the raw copy number was estimated as the number of reads confidently mapped (mapping
quality >35) divided by the median of such value across all windows in the genome, then multiplied by two (to reflect diploid
genomes). A hidden Markov model (HMM) was then used to perform the segmentation. Each state in the HMM corresponds to a
discrete copy number value. The emission probability was modeled as a single Gaussian probably density function. A standard
Viterbi algorithm was used to estimate the HMM parameters and
determined the segmentation. We derived copy number altered
regions (CNARs) by comparing the segmentation of the tumor
genome versus that of the normal genome. A log likelihood ratio
(LLR) score was computed for each CNAR to quantify the possibility of being a true CNAR from being the null (copy number
neutral) hypothesis. Calls with LLR score <20 were dropped from
further consideration.

Structural variation (SV) analysis
Structural variants (SVs) were predicted by BreakDancer 9 with
TIGRA_SV assembly 10, SquareDancer (Wang et al. 2011), and
Pindel (Ye et al. 2009). Copy number differences with regions of SV
were determined by BreakDancer (Chen et al. 2009). Putative SVs
from BreakDancer were chosen for localized, de novo assembly if
they (1) had at least two supporting discordant read pairs in the
tumor, but none in the normal, (2) were supported by a copy
number change of >0.5 in the SV region, (3) affected a coding exon,
or (4) had one or more breakpoints in any part of a known cancer
gene. SV regions were defined as 6500 bp from the predicted
breakpoints. The depth-weighted average contig length was used
as a quality measure of the assembly:
M1

+ d i li
q¼

Capture alignment, de-duplication, and BAM file generation
Illumina reads were aligned individually to the Ensembl release 45
version of Human NCBI Build 36 using BWA 2 v0.5.7 with soft
trimming (-q 5) as previously reported (Mardis et al. 2009). For each
sample, individual lane alignments in BAM format were merged
together using SAMtools 3 r544. Duplicates were marked in the
merged BAM files by the MarkDuplicates class of Picard 4 v1.17.
Reads with mapping quality of zero, or that were marked as duplicates by Picard, were excluded from further analysis.
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i¼0
M1

;

+ di
i¼0

where li and di are the length and the average depth of contig i,
respectively, and M is the total number of contigs in the TIGRA
assembly. Short contigs (<30 bp) that are assembled from the homopolymer reads are excluded in the calculation. We found this
statistic properly summarizes both the size and the coverage and
therefore is more informative to measure the assembly quality
than the N50 size. Based on our manual examination of the
alignment results, we found that the high-quality assemblies that
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contain valid sequence frequently have q > 100 bp. Once assembled, contigs were aligned to their respective local reference sequences (SV region 6700 bp; NCBI Build b36) using cross_match
v1.080721 with the parameters ‘‘–bandwidth 20 –minmatch 20
–minscore 25 –penalty –10 –discrep_lists –tags –gap_init –10 –gap_ext
–1’’. Contigs whose alignments had more than two segments or
were significantly different from the reference (one segment with
substitution >0.006 or indel rate of >0.002; or two segments with
substitution rate >0.005, indel rate of >0.001, or more than five
inserted/deleted bases) were removed. A complementary in-house
algorithm, SquareDancer, was used to identify candidate SVs by
utilizing soft-clipping information from the BWA aligner. Large
deletions and moderately sized insertions were also predicted using a modified version of the Pindel 7 tool. Pindel calls with read
support in the tumor but not the normal, as well as calls supported
by copy number evidence from cnvHMM (copy number >0.5) were
identified. Candidate SVs from BreakDancer, SquareDancer, and
Pindel SV regions from different methods that overlapped >75%
(allowing a buffer of 650 bp) were merged into a single event.

PCR-based validation and screening
Using Primer3, universal-tailed PCR primers were designed to
amplify all coding exons of NF1 in addition to the localized region
surrounding all predicted nonsynonymous coding variants. Tumor DNA was PCR-amplified using AmpliTaq Gold PCR Master
mix and sequenced using BigDye 3.1 Sequencing Kits and loaded
on ABI 3730xl capillary sequencers. Data were assembled using
Consed and putative mutations identified using Polyscan and
Polyphred. All putative variants were visually reviewed to eliminate artifacts.

Hybridization validation data analysis
To validate predicted nonsynonymous coding SNVs and small (<3
bp) indels, we used VarScan 2.2.11 with the following parameters:
–mincoverage 30 –min-var-freq 0.08 –P-value 0.10 –somatic-P-value
0.01 –validation 1. To validate low-frequency (2%–8%) SNVs, we
reran VarScan with adjusted parameters: –min-coverage 100 –minvar-freq 0.02 –P-value 0.10 –somatic-P-value 0.01 –validation 1. In
validation mode, VarScan reads data from tumor and normal
samples simultaneously, performing pairwise comparisons at
every position covered in both samples. Each position is classified as Reference (wild type), Germline, LOH, or Somatic, based
upon a comparison of the consensus genotypes and supporting
read counts (Fisher’s exact test). Positions called Somatic are
further subjected to our internally developed false-positive filter
that removes sequencing- and alignment-related artifacts using
several criteria (read count, mapping quality, average read position, strand representation, homopolymer-like sequence context, mismatch quality sum difference, trimmed read length, Q2
distance).

Mutation rate and spectrum analysis
Mutation rate analyses utilized validated nonsynonymous coding
SNVs, high-confidence SNVs in potential regulatory regions, and
SNVs in nonrepetitive regions that passed visual inspection. For
the mutation rate calculation, the number of SNVs in each bin was
compared to the overall size of the exome, noncoding genome
with regulatory potential, and remaining nonrepetitive genome,
which on NCBI Build 36, consisted of 43.89 Mbp, 248.21 Mbp, and
1198.99 Mbp, respectively. The individual mutation rates (mutations per megabase) were calculated independently then combined for all three bins to determine the overall mutation rate.

Methylation analysis
Methylation state was determined using the Infinium HumanMethylation450 BeadChip Kit (Gu et al. 2010; Bibikova et al.
2011; Sandoval et al. 2011). The HumanMethylation450 chip
arrays >485,000 methylation sites per sample at single-nucleotide resolution. Aside from covering 96% of CpG islands, sites are
also associated with regions of biological interest—e.g., miRNA
promoter regions, differentially methylated sites identified in
tumor versus normal (multiple forms of cancer) and across
several tissue types—for epigenome-wide association studies
(EWAS). Of the >485,000 sites on the Infinium array, 42 of the
probes are located within the NF1 gene footprint (including
upstream promoter region). The NF1 probes include UCSC-defined CpG island annotation (i.e., island, shore, and shelf designations). The 42 probes culled from the NF1 gene footprint
have 13 probes associated with genes on the opposite strand of
NF1: six for OMG, two for EVI2B, and five for EVI2A. These 42
probes were reviewed for methylation state across three different
pilocytic astrocytomas from patients with known NF1 defects
and two spontaneous pilocytic astrocytomas without NF1 defects. Infinium chip Beta-values (the ratio of the methylated
probe intensity and the overall intensity: the sum of methylated
and unmethylated probe intensities) were converted to M-values16
(log2 ratio of the intensities of methylated probe versus unmethylated probe) using the MethyLumi package from Bioconductor19
(Davis et al. 2012). Illumina’s raw IDAT files were fed to the
MethyLumi package for value conversion. Resulting M-values
were tracked/interrogated across our samples by converting to
YAML format, with subsequent parsing mediated by Perl scripts
developed in-house. In this manner, M-values related to the 42
NF1-specific probes were collected and contrasted for our samples. Values were imported and manually reviewed as custom
tracks in the UCSC Genome Browser (Kent et al. 2002) as methylation probe tracks, as well as M-value heat map blocks across
our tumor and sporadic samples. Differences in M-values (D
M-values) were calculated across our samples, in a pairwise roundrobin fashion, with standard deviation used to assess significance
in differential change. As values were assessed localized to the
42 probe NF1 gene region, a follow-up global assessment was
undertaken for all 485,000+ probes across all samples, to review
global significance of change, as D M-values, between samples.
Our five tumor samples were evaluated in an all-versus-all fashion with 4,855,770 comparison values sampled in total. The
mean D M-value was 0.52, standard deviation being 0.58. Any
change in M-value >2.24 would be 3 standard deviations. For our
purposes, we scaled back to an absolute D M-value of $2.0 in
value being ‘‘significant’’. This provided 137,628 comparisons
matching the criteria (or only 2.83% of the total 4,855,770 crosscomparisons being relatively significant). Accepting these values
as being representative of the sensitivity for the technology (i.e.,
not ‘‘error’’), any D M-value $2.0 within NF1 would be considered significant. In addition, we performed a t-test to identify
regions genome-wide exhibiting significantly differential methylation per probe. We clustered together probes 200 bp or closer with
P # 0.05 and determined 118 such probes in 105 clusters that
exhibited significantly differential methylation. These regions
were further annotated by identifying all genes occurring within
10 kbp (Supplemental Table 2).

Immunohistochemistry and qRT-PCR
Immunohistochemistry and real-time quantitative RNA RT-PCR
were performed as previously reported (Gutmann et al. 2000;
Sharma et al. 2007).
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Data access
All sequence data have been submitted to the database of Genotypes and Phenotypes (dbGaP) (http://www.ncbi.nlm.nih.gov/
gap) under accession number phs000563.v1.p1.
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